The treatment of multiple sclerosis (MS) has evolved remarkably over the past 25 years. This progress has been enabled by advances in research, drug development and active engagement of the scientific ...
Neurofilament light chain is a promising noninvasive biomarker for multiple sclerosis (MS), but lacks disease specificity due to other neurological causes. Apolipoprotein levels are negatively ...
A 43 year-old man had a twenty year history of MS, presenting initially with optic neuritis. Over the past ten years, he developed progressive weakness, numbness and ataxia in the lower extremities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results